Presented By: Judith Kuntsche, Ph.D., University of Southern Denmark, and Christoph Johann, Ph.D., Wyatt Technology
Presented Live: January 28, 2020
One of the primary challenges in developing and commercializing novel nanoparticle-based therapies is detailed characterization of the formulation components. FFF-DLS-MALS technology, which couples light scattering and other online detectors to field-flow fractionation, addresses this challenge. This webinar explores applications of FFF-DLS-MALS to characterize nanoparticle drug- and gene-delivery formulations, to determine high-resolution size distributions, drug loading and release, and particle structure.
The focus of this webinar is on colloidal lipid-based formulations, such as nanoemulsions and liposomes, that can be used to formulate poorly-water-soluble drugs in aqueous preparations to facilitate intravenous administration. FFF-DLS-MALS provides a very useful analytical tool to investigate the behavior of such formulations, even in complex physiological media such as serum. Case studies presented include: measurement of detailed liposome size distributions; assessment of drug release and transfer to cell membrane proxies; particle morphology; quantification of co-existing colloidal structures; and stability of the nanocarriers. The relevance of FFF-DLS-MALS to meeting FDA requirements for liposome formulations are also discussed.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.